MedTrace Logo

Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder

NCT01659736 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2016-04-27

Study results available
· View outcomes & findings →

Summary

This study is investigating a new indication of Transcranial Magnetic Stimulation (TMS) by conducting a pilot randomized-controlled trial (RCT) comparing structural neuronavigation-directed TMS to Sham-TMS Placebo therapy for treatment of Generalized Anxiety Disorder (GAD).

Conditions

  • Generalized Anxiety Disorder

Interventions

DEVICE

TMS

Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.

Sponsors & Collaborators

  • Neuronetics

    collaborator OTHER

  • Hartford Hospital

    lead OTHER

Principal Investigators

  • Gretchen J Diefenbach, Ph.D. · Hartford Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01659736 on ClinicalTrials.gov